Percutaneous Left Atrial Appendage Closure (LAAC)

CMS covers percutaneous LAAC for non-valvular atrial fibrillation only under Coverage with Evidence Development (CED) when FDA‑approved devices are used and multiple program, operator, patient, and registry/RCT requirements are met. Key patient criteria include CHADS2 ≥ 2 or CHA2DS2‑VASc ≥ 3, documented shared decision making, and inability to take long‑term oral anticoagulation despite suitability for short‑term warfarin; coverage also requires CMS‑approved registry participation or CMS‑approved RCT enrollment, operator training and volume thresholds, and appropriate documentation and public reporting of study/registry outcomes.

"Percutaneous left atrial appendage closure (LAAC) is covered for patients with non-valvular atrial fibrillation (NVAF) when furnished under Coverage with Evidence Development (CED) and the implante..."

Sign up to see full coverage criteria, indications, and limitations.